The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer.
作者信息
Hurwitz Mark D
机构信息
Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
出版信息
Transl Androl Urol. 2019 Jul;8(Suppl 3):S303-S306. doi: 10.21037/tau.2019.06.09.
Abstract
摘要
相似文献
1
The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer.多西他赛之争：化疗对高危非转移性前列腺癌的影响
Transl Androl Urol. 2019 Jul;8(Suppl 3):S303-S306. doi: 10.21037/tau.2019.06.09.
2
The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.二甲双胍在多西他赛化疗期间对接受去势抵抗性前列腺癌治疗的糖尿病患者前列腺癌特异性和总生存的影响。
J Urol. 2017 Apr;197(4):1068-1075. doi: 10.1016/j.juro.2016.10.069. Epub 2016 Oct 28.
3
A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy.一名患有严重全血细胞减少症的去势抵抗性转移性前列腺癌患者，接受多西他赛化疗成功治愈。
J Oncol Pharm Pract. 2020 Jul;26(5):1254-1258. doi: 10.1177/1078155219890653. Epub 2019 Nov 27.
4
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.雄激素剥夺疗法单独或联合多西他赛治疗非去势转移性前列腺癌（GETUG-AFU 15）：一项随机、开放标签、3 期临床试验。
Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8.
6
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.多西他赛和达沙替尼或安慰剂治疗转移性去势抵抗性前列腺癌男性患者（READY）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2013 Dec;14(13):1307-16. doi: 10.1016/S1470-2045(13)70479-0. Epub 2013 Nov 8.
7
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.临床试验参与与不参与对转移性去势抵抗性前列腺癌接受一线多西他赛化疗的男性总生存期的影响。
BJU Int. 2012 Dec;110(11 Pt B):E575-82. doi: 10.1111/j.1464-410X.2012.11286.x. Epub 2012 Jun 15.
8
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.优化转移性去势抵抗性前列腺癌的抗癌治疗：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 May 20;36(15):1521-1539. doi: 10.1200/JCO.2018.78.0619. Epub 2018 Apr 2.
9
Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.多西他赛为基础的化疗联合地塞米松 1mg 每日口服治疗去势抵抗性前列腺癌：长期结果。
Int J Urol. 2019 Aug;26(8):797-803. doi: 10.1111/iju.14009. Epub 2019 May 5.
10
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.一项针对接受多西他赛化疗的日本转移性去势抵抗性前列腺癌男性患者的醋酸阿比特龙2期研究。
Jpn J Clin Oncol. 2014 Dec;44(12):1206-15. doi: 10.1093/jjco/hyu148. Epub 2014 Oct 1.
引用本文的文献
1
Nanotechnology Driven Cancer Chemoradiation: Exploiting the Full Potential of Radiotherapy with a Unique Combination of Gold Nanoparticles and Bleomycin.纳米技术驱动的癌症放化疗：通过金纳米颗粒与博来霉素的独特组合充分发挥放射治疗的潜力
Pharmaceutics. 2022 Jan 20;14(2):233. doi: 10.3390/pharmaceutics14020233.
2
Docetaxel-Mediated Uptake and Retention of Gold Nanoparticles in Tumor Cells and in Cancer-Associated Fibroblasts.多西他赛介导的金纳米颗粒在肿瘤细胞和癌症相关成纤维细胞中的摄取与滞留
Cancers (Basel). 2021 Jun 24;13(13):3157. doi: 10.3390/cancers13133157.
本文引用的文献
1
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.多西他赛化疗联合雄激素抑制和放疗治疗局限性高危前列腺癌的效果：NRG 肿瘤学 RTOG 0521 随机 III 期试验。
J Clin Oncol. 2019 May 10;37(14):1159-1168. doi: 10.1200/JCO.18.02158. Epub 2019 Mar 12.
2
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.局部治疗后前列腺特异性抗原水平持续升高的高危前列腺癌患者中添加多西他赛的雄激素剥夺治疗的效果：一项随机临床试验。
JAMA Oncol. 2019 May 1;5(5):623-632. doi: 10.1001/jamaoncol.2018.6607.
3
Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.前列腺特异性抗原持续存在于前列腺切除术后男性中预测转移的前列腺癌基因组分类器的性能。
Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10.
4
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.前列腺癌 Luminal 和基底分型与预后和雄激素剥夺治疗反应的关联。
JAMA Oncol. 2017 Dec 1;3(12):1663-1672. doi: 10.1001/jamaoncol.2017.0751.
5
Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.辅助放疗、雄激素剥夺治疗及多西他赛用于前列腺癌根治术后高危前列腺癌：NRG肿瘤学/放射肿瘤学组（RTOG）0621研究结果
Cancer. 2017 Jul 1;123(13):2489-2496. doi: 10.1002/cncr.30620. Epub 2017 Mar 21.
6
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.多西他赛、唑来膦酸或两者联合添加至前列腺癌一线长期激素治疗（STAMPEDE）：一项适应性、多组、多阶段、平台随机对照试验的生存结果
Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.
7
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.在局限性或转移性激素敏感性前列腺癌男性患者的标准治疗中添加多西他赛或双膦酸盐：汇总数据的系统评价和荟萃分析
Lancet Oncol. 2016 Feb;17(2):243-256. doi: 10.1016/S1470-2045(15)00489-1. Epub 2015 Dec 21.
8
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.雄激素剥夺疗法 (ADT) 联合多西他赛与单独 ADT 治疗转移性去势抵抗性前列腺癌：转移负担的影响和 GETUG-AFU15 随机 3 期试验的长期生存分析。
Eur Urol. 2016 Aug;70(2):256-62. doi: 10.1016/j.eururo.2015.11.005. Epub 2015 Nov 21.
9
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
10
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.雄激素剥夺疗法联合多西他赛和雌莫司汀与单独雄激素剥夺疗法治疗高危局限性前列腺癌（GETUG 12）：一项 3 期随机对照临床试验。
Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.
Zotero 插件